Date: 2017-02-23
Type of information: Opening of new premises
Compound: antibody-drug conjugate (ADC) bioconjugation unit
Company: Novasep (France)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On February 23, 2017, Novasep announced that its new €11 million bioconjugation facility is now operational. The greenfield facility was erected within 20 months on Novasep’s Le Mans site in France. The 2,000m2 facility features two flexible GMP production suites equipped with 10L to 400L vessels to support both clinical and commercial manufacturing of antibody-drug conjugates. The stand-alone facility is purpose-built and offers R&D services, QC and scale-up laboratories. The new unit completes Novasep’s antibody-drug conjugate manufacturing platform already featuring antibody-drug conjugate payloads, drug linkers and monoclonal antibody commercial scale production capabilities.
Financial terms:
Latest news:
